Blog

Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer

Photo of Paolo Tarantino from X

Apr 16, 2024, 00:17

Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:

“In our latest article, just published on ESMO Open, we review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer.

Thanks to AstraZeneca for supporting this publication and to H. Earle for bravely sharing with us and the journal readers her personal experience while receiving treatment with T-DXd.

See link here.”

Paolo Tarantino

Source: Paolo Tarantino/LinkedIn

AstraZeneca cancer Dana-Farber Cancer Institute ESMO Open Future Perspectives H. Earle HER2-low Breast Cancer latest article medical journal OncoDaily Oncology Paolo Tarantino Personal Experience T-Dxd

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage